F10 and venous thromboembolism: Four direct-acting oral anticoagulants (DOAC)- the thrombin inhibitor dabigatran, and Factor Xa inhibitors rivaroxaban, apixaban, edoxaban [3–6]—are now approved for non-valvular atrial fibrillation and venous thromboembolism treatment (all four), secondary VTE prevention (rivaroxaban, apixaban, dabigatran), prophylaxis from venous thromboembolism after knee or hip replacement (dabigatran, rivaroxaban, apixaban) [7].